PROFESSOR XX Sample Clauses

PROFESSOR XX. XXXXXX XXXXX MAHAMD ADIKAN Vice-Chancellor SIGNED BY For and on behalf of AAA ………………………………………………………… [ name and designation ] In the presence of: ……………………………………………………….. [ HoD’s name and designation ] In the presence of: ……………………………………………………….. [ name and designation ]
Sample 1Sample 2See All (4)
AutoNDA by SimpleDocs
PROFESSOR XX. Xxxx Xxxxx, CEO of BioNTech AG commented: “We are delighted to collaborate with a leading cancer immunotherapy company such as Genentech. Supported by its extensive tumor immunology understanding, BioNTech has been building clinical experience with its proprietary mRNA vaccines in a number of cancer types over several years. Combining BioNTech’s broad proprietary capabilities in the design, formulation, manufacturing and clinical testing of individualized neoantigens-based mRNA vaccines with Genentech’s eminent cancer immunotherapy, diagnostic, manufacturing and commercial expertise, will allow us, on a global scale, to drive forward the development of individualized vaccines to the market to treat a broad range of cancers. Xxxx Xxxxxx, COO of BioNTech added: ”This alliance underpins BioNTech’s strategy of collaborating with companies that are committed to developing truly disruptive immunotherapies and its long term ambitions of bringing its own products to market .” “Unlike any medicine we have ever developed, virtually all cancer patients may potentially benefit from a custom built cancer vaccine,” said Xxxxx Xxxxx, M.D., Ph.D., Senior Vice President and Global Head of Genentech Partnering. “By collaborating with BioNTech on this cutting edge approach, we hope to truly advance cancer treatments by using a common molecular backbone – mRNA – that is uniquely tailored to an individual patient.” BioNTech will continue to develop its non-neoepitope mRNA cancer vaccines outside of the collaboration. The completion of the agreement is subject to customary closing conditions, including clearance under the Xxxx-Xxxxx-Xxxxxx Antitrust Improvements Act, and is expected to occur in the fourth quarter of 2016. For more information, please contact: BioNTech XX Xxxx Xxxxxx, for BioNTech AG Xxxxxx Xxxxx Xxxx Xxxxx, Xxx Xxxx, Xxxxxx Xxxxx Tel: +00 (0) 0000 0000 0000 Tel: +00 (0) 00 0000 0000 Email: Xxxxxx.Xxxxx@xxxxxxxx.xx Email: xxxxxxxx@xxxxxxxxxx.xxx About BioNTech AG BioNTech AG is an immunotherapy leader with bench-to-market capabilities, developing truly personalized, well-tolerated and potent treatments for cancer and other diseases. Established by clinicians and scientists the Group is pioneering disruptive technologies ranging from individualized mRNA based medicines through innovative Chimeric Antigen Receptors /T-cell Receptor-based products and novel antibody checkpoint immunomodulators. BioNTech’s clinical programs are supported by an in-house molecular dia...
Sample 1Sample 2
PROFESSOR XX. XXXXXX XXXXX MAHAMD ADIKAN Vice-Chancellor SIGNED BY for and on behalf of AAA ........................................................................ [ name & designation ] In the presence of: ……………………………………………………… [ HoD’s name & designation ] In the presence of: ……………………………………………………… [name & designation ] SCHEDULE A DESCRIPTION OF THE ORIGINAL MATERIAL ………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… Any information about the Material supplied shall be kept confidential and any publication shall be first approved by USM in writing. The Material is the exclusive property of USM. SCHEDULE B NAMES AND PARTICULARS OF THE PERSONNEL UNIVERSITI SAINS MALAYSIA 1. *** 2. *** AAA
Sample 1
PROFESSOR XX. XXXXXX XXXXX MAHAMD ADIKAN Vice-Chancellor Signed for and on behalf of AAA in the presence of : ............................................................. [ name & designation of witness ] ) ) ) ................................................................................... [ name & designation ] ANNEXURE A THE INVENTION ANNEXURE B
Sample 1
PROFESSOR XX. Xxxxxxx Xxxxxxx, Professor, Xx. Xxxxxx Xxxxx, Head, Laboratory of Molecular Biology of Protists. The Foundation reserves the right to terminate the Grant if any of the aforementioned individuals or other key personnel leave the project during the term of the Grant.
Sample 1

Related to PROFESSOR XX

  • Professor Vocational Credential, Master’s Degree, and 14 years experience Vocational Credential, Bachelor’s Degree, and 16 years experience

  • PROFESSORS, TEACHERS AND RESEARCHERS 1. An individual who is a resident of a Contracting State immediately before making a visit to the other Contracting State, and who, at the invitation of any university, college, school or other similar educational institution which is recognized by the competent authority in that other Contracting State, visits that other Contracting State for a period not exceeding two years solely for the purpose of teaching or research or both at such educational institution shall be exempt from tax in that other Contracting State on any remuneration for such teaching or research.

  • Assistant Professor An Assistant Professor is a member of a Faculty of the University who shall ordinarily have the following minimum qualifications:

  • AT&T 9STATE shall be defined as the States of Alabama, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina and Tennessee.

  • PROFESSORS AND TEACHERS A professor or teacher who makes a temporary visit to a Contracting State for a period not exceeding two years for the purpose of teaching or conducting research at a university, college, school or other educational institution, and who is, or immediately before such visit was, a resident of the other Contracting State shall be exempt from tax in the first-mentioned Contracting State in respect of remuneration for such teaching or research.

  • Associate Professor 5. Professor

  • FEDERAL MARITIME COMMISSION Ocean Transportation Intermediary License Applicants The Commission gives notice that the following applicants have filed an application for an Ocean Transportation Intermediary (OTI) license as a Non- Vessel-Operating Common Carrier (NVO) and/or Ocean Freight Forwarder (OFF) pursuant to section 19 of the telephone at (202) 523–5843 or by email at XXX@xxx.xxx. 5G Logistics Solutions LLC (NVO & OFF), 0000 XX 000xx Xxxxx, Xxxxx, XX 00000. Officers: Xxxxxxxx Xxxxxx, President (QI), Xxxxxxx X. Xxxxx, Vice President. Application Type: New NVO & OFF License. American Cargo International, Inc. (NVO & OFF), 0000 XX 00xx Xxxxxx, Miami, FL 33128. Officers: Xxxxx Xx Xxx, Vice President (QI), Xxxxx Xxxxxxxx, Member. Application Type: License Transfer to American Cargo International, LLC. Atlanta Customs Brokers & Intl Freight Forwarders Inc dba ACB Ocean Services (NVO & OFF), 000 Xxxxxxx Xxxxx Xxxxxxx, Xxxxx 000, Xxxxxxx, XX 00000. Officers: Xxxxx Xxxxxxxx, Vice President Exports (QI), Xxxxxx Xxxxxx, President. Application Type: New NVO & OFF License. Xxxxxxx International Transport, L.L.C. (NVO & OFF), 0000 Xxxxxxxxxx Xxxxxxx, XxXxxxxxx, XX 00000. Officers: Xxxxxx X. Xxxxxxxx, Vice President (QI), Xxxxxx X. Xxxxxx, Managing Member. Application Type: QI Change. CMS Shipping Agency, Inc. dba Atlantic Pacific Lines (NVO & OFF), 0000 Xxxxxxxx, Xxxxx 000, Xxxx Xxxx Xxxxxx, XX 00000. Officer: Xxxxxx Xxxxxxx, President (QI). Application Type: Name Change to Atlantic Pacific Lines, Inc, dba Atlantic Pacific Lines. DBN Carrier, Inc. (NVO), 000 X. Xxxxxxxx Avenue, Suite 5B, Los Angeles, CA 90036. Officers: Xxxxxxxxxx Xxxxxxxxxx, President (QI), Xxxxxxx Xxxxxxxxxx, Secretary. Application Type: New NVO License. Xxxxxx Xxxxxxxxx dba Galaxy Enterprises LA (NVO), 00000 Xxxxxxx Xxxx., Xxxxx 00, Xxxxxxx Xxxx, CA 91403. Officer: Xxxxxx Xxxxxxxxx, Sole Proprietor (QI). Application Type: New NVO License. Forward Systems Group, Inc. (NVO & OFF), 1915 NW 00xx Xxxxxx, Xxxxx, XX 00000. Officers: Xxxxxxx Xxxxxxx, President (QI), Xxxxx X. Xxxxxxx, COO. Application Type: New NVO & OFF License. Xxxxx X. Xxxxx & Co. dba JJB Global Logistics Co., Ltd. dba JJB Inland Logistics JJB Link Logistics Company 0000 Xxxxxxxxxx Xxxx, Xxxxx 000, Xxxxxxx, XX 00000. Officers: Xxxxxx Xxxxxx, President (QI), Xxxxxx Xxxxx, Secretary. Application Type: New NVO & OFF License. NMC Logistics Solutions, Inc. (NVO & OFF), 0000 XX 00xx Xxxxxx, Xxxxx, XX 00000. Officers: Xxxxxxx Xxxxxxx, President (QI), Xxxxx Xxxxxx, Secretary. Application Type: New NVO & OFF License. Platinum Cargo Logistics, Inc. (NVO & OFF), 00000 X. Xxx Xxxx Avenue, Torrance, CA 90501. Officers: Xxxxxx

  • General Management In the discharge of its general duty to manage the successful performance of the Services, Vendor shall:

  • Professional Development Leave A. Policy. Professional development leave shall be made available to employees who meet the requirements set forth below. Such leaves are granted to increase an employee's value to the University through enhanced opportunities for professional renewal, educational travel, study, formal education, research, writing, or other experience of professional value, not as a reward for service.

  • Specialist A dentist who focuses on a specific area of dentistry, including oral surgery, endodontia, periodontia, orthodontia and pediatric dentistry, or a group of patients to diagnose, manage, prevent or treat certain types of symptoms and conditions. Spouse: The person to whom the Subscriber is legally married, including a same sex Spouse. Spouse also includes a domestic partner. Subscriber: The person to whom this Contract is issued. UCR (Usual, Customary and Reasonable): The cost of a dental service in a geographic area based on what Providers in the area usually charge for the same or similar medical service. Us, We, Our: BlueShield of Northeastern New York and anyone to whom We legally delegate performance, on Our behalf, under this Contract. Utilization Review: The review to determine whether services are or were Medically Necessary or experimental or investigational (including treatment for a rare disease or a clinical trial). You, Your: The Member.

Time is Money Join Law Insider Premium to draft better contracts faster.